SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee Therapeutics entered into an exclusive worldwide license…

Apogee Therapeutics, Inc. · 8-K filed Jun 22, 2026 at 07:22 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Jun 22, 2026 at 07:22 ET

Apogee Therapeutics entered into an exclusive worldwide license agreement with Paragon Therapeutics for antibodies targeting IL-31R, a novel pipeline asset. The deal includes up to $23.25 million in development and regulatory milestones plus low-single-digit royalties on net sales. This expands Apogee's pipeline into a new target for inflammatory diseases but remains at the preclinical stage with no near-term catalysts.

  • Exclusive worldwide license from Paragon for IL-31R-directed antibodies
  • Up to $23.25 million in milestone payments: $5.25M (Phase I), $3M (Phase II), $5M (Phase III), $10M (FDA approval)
  • Low-single-digit royalty on net sales of licensed products
  • Optional CMC activities with fees ranging from $1.3M to $2.0M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access